<DOC>
	<DOCNO>NCT00354653</DOCNO>
	<brief_summary>The efficacy lamivudine Hepatitis Be Antigen ( HBeAg ) positive Asian patient chronic hepatitis well established.The evidence HBeAg negative patient limit . Limited sustained response observe post-treatment follow one year treatment period . Whether result apply patient Iran uncertain . This study therefore intend assess efficacy profile two year open treatment adult Iranian population .</brief_summary>
	<brief_title>A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Confirmed active liver disease due Hepatitis B virus . Patients must adequate blood &amp; liver function . Female patient childbearing potential must non pregnant willing abstain intercourse 2 week prior administration first dose study medication 28 day final dose study medication willing consistently correctly use acceptable method birth control . Patients serious concurrent illness hepatitis B like cancer , severe heart disease , uncontrolled diabetes mellitus AIDS eligible . Persons allergic lamivudine suffer hepatitis C , D E infection take alcohol eligible .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>HBeAg</keyword>
	<keyword>HBV</keyword>
	<keyword>CHRONIC HEPATITIS</keyword>
	<keyword>lamivudine</keyword>
</DOC>